DERMATA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $2.9M | $8.2M | $4.1M | $5.7M | $3.5M | $1.6M |
| SG&A Expense | — | $4.8M | $4.3M | $4.0M | $4.0M | $4.4M | $1.6M |
| Operating Income | — | $-7.8M | $-12.5M | $-8.0M | $-9.7M | $-7.9M | $-3.2M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | $45.6K | $197.3K |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-7.6M | $-12.3M | $-7.8M | $-9.6M | $-7.9M | $-3.2M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-8.16 | $-13.39 | $-6.67 | $-2.32 | $-0.41 | $-0.14 |
| EPS (Diluted) | — | $-8.16 | $-13.39 | $-6.67 | — | — | — |
| Shares Outstanding (Basic) | 4.0M | 926.2K | 917.8K | — | 4.6M | 25.8M | 22.9M |
| Shares Outstanding (Diluted) | 4.0M | 926.2K | 917.8K | 1.2M | 4.6M | 25.8M | 22.9M |
| Dividends Per Share | — | — | — | — | — | — | — |